UroToday12h
ESMO 2024: Invited Discussant: Efficacy of SPLASH and UpFrontPSMA Trials
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a proffered paper session for prostate ...
UroToday16h
ESMO 2024: Controversies in Testis Cancer: Escalation or De-escalation?
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a session focusing on rare ...
UroToday16h
ESMO 2024: Updates in Penile Cancer
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a session focusing on rare ...
UroToday16h
ESMO 2024: Prospective COTRIMS (COlogne Trial of Retroperitoneal Lymphadenectomy in Metastatic Seminoma) Trial – 3 Year Update
(UroToday.com) The 2024 ESMO annual meeting included a session on testicular cancer, featuring a presentation by Dr. Axel Heidenreich discussing the 3 year update of the prospective COTRIMS trial.
UroToday16h
ESMO 2024: Assessment of the Utility of CT Scans in the Long-Term Follow-up of Metastatic Non-Seminomatous Germ Cell Tumors: The Late CT Study
(UroToday.com) The 2024 ESMO annual meeting included a session on testicular cancer, featuring a presentation by Dr. Deep Chakrabarti discussing the Late CT study assessing the utility of CT scans in ...
UroToday1d
ESMO 2024: Hematologic Impact of [177Lu]Lu-PSMA-617 Versus ARPI Change in Patients with Metastatic Castration-Resistant Prostate Cancer in PSMAfore
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the presentation of poster 1611. Dr. Kim Chi discussed the hematologic impact ...
UroToday1d
ESMO 2024: Enzalutamide with or Without Leuprolide in Patients with High-Risk Biochemically Recurrent Prostate Cancer: EMBARK Post Hoc Analysis by Age
(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Neal Shore discussing a post hoc analysis from EMBARK focusing on age. Patients ...
UroToday1d
ESMO 2024: Will Theranostics Become Standard of Care?
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the session Therapeutic options beyond AR pathway inhibitors: What do we choose ...
UroToday1d
ESMO 2024: Novel Therapeutic Approaches for ARPI-resistant Disease
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 17th was host to the session Therapeutic options beyond AR ...
UroToday1d
Advanced Prostate Cancer Videos
Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin ...
UroToday1d
ESMO 2021 – Final Overall Survival Analysis From ARCHES, Results of Expanded Cohort 6 of the COSMIC-021 Study and Highlights in Prostate Cancer
Neeraj Agarwal presented results of the COSMIC-021 cohort 6, examining the role of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Dr. Agarwal ...
UroToday2d
IBCN 2024: Investigating BCG Induced B Cell Responses in Patients with Non-Muscle Invasive Bladder Cancer
(UroToday.com) The 2024 IBCN annual meeting included a session on advancements in circulating biomarkers, featuring a presentation by Dr. Priyanka Yolmo discussing BCG-induced B cell responses in ...